At AstraZeneca, Patient Safety is a fundamental company principle. We aim to protect patients by minimizing the risks whilst maximizing the benefits of our medicines.   To support this, AstraZeneca maintains a comprehensive worldwide system for Patient Safety, collecting, investigating and proactively evaluating adverse events associated with the use of our products. All adverse events will be evaluated and the safety of the products for patients assessed by dedicated teams of scientists, so that we can provide accurate information and advice regarding the appropriate use of our products to all healthcare providers.   Last update 25 May 09       - Every drug must be assessed for quality, efficacy and safety before and continuously after it is granted a license. - Patient Safety is responsible for the monitoring, collection, analysis, response to and communication of safety data. - Safety data is derived from reports of Adverse Drug Reaction and this allows AstraZeneca to accurately represent the risk and benefit of a drug.